Diffuse Large B Cell Lymphoma  >>  Monjuvi (tafasitamab-cxix)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Monjuvi (tafasitamab-cxix) / Incyte
FIRST-MIND, NCT04134936: Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Calendar Jan 2026 - Dec 2026: Regulatory approval in US in combination with Revlimid for frontline DLBCL
Checkmark Result from firstMIND trial for 1L DLBCL at ASH 2022
Dec 2022 - Dec 2022: Result from firstMIND trial for 1L DLBCL at ASH 2022
Checkmark Results rom First-MIND trial for newly diagnosed DLBCL
Jun 2021 - Jun 2021: Results rom First-MIND trial for newly diagnosed DLBCL
More
Completed
1
66
Europe, US, RoW
Tafasitamab, Tafasitamab plus lenalidomide
MorphoSys AG
Diffuse Large B-cell Lymphoma
02/21
08/22
CCTG LY18-A, NCT04161248: Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma

Recruiting
1
18
Canada
Venetoclax, Rituximab Injection, Rituximab SC, Gemcitabine, Dexamethasone, Cisplatin, Glofitamab, Tafasitamab
Canadian Cancer Trials Group, Roche Pharma AG, AbbVie, Incyte Corporation
Lymphoma, B-Cell
12/25
07/26

Download Options